Cross et al
Outcomes on 174 T-PLL pts
RMH 1989-2019
#Alemtuzumab used in 116 pts, 59% 1L + 41% as subsequent line.
median OS 20.6 months
*NO* improvement in OS over 30 years.
Brutal disease.
We need more international clinical trials + engagement from industry! #ASH19pic.twitter.com/PhwYIdr24j
1:19 AM - 11 Nov 2019
0 replies
11 retweets
18 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.